LUPIN · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 69/100 — Quality 79 · Valuation 60 · Growth 76 · Momentum 50
| Share price | ₹2,478.50 |
| Market cap | ₹1.05 lakh Cr |
| P/E ratio | 22.7 |
| P/B ratio | 5.4 |
| ROE | 23.9% |
| ROCE | 21.2% |
| Dividend yield | 0.52% |
| Book value | ₹429.87 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹27,958 Cr | ₹5,355 Cr | 29.0% |
| 2025 | ₹22,708 Cr | ₹3,306 Cr | 23.0% |
| 2024 | ₹20,011 Cr | ₹1,936 Cr | 19.0% |
| 2023 | ₹16,642 Cr | ₹448 Cr | 10.0% |
| 2022 | ₹16,405 Cr | ₹-1,528 Cr | 1.0% |
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, wo